Scarica l'app Stockscreener
27.43
3.31%
0.88
Dopo l'orario di chiusura:
27.65
0.22
+0.80%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Precedente Chiudi:
$26.55
Aprire:
$26.885
Volume 24 ore:
1.58M
Relative Volume:
1.16
Capitalizzazione di mercato:
$5.58B
Reddito:
-
Utile/perdita netta:
$-464.20M
Rapporto P/E:
-10.23
EPS:
-2.6823
Flusso di cassa netto:
$-423.09M
1 W Prestazione:
+10.92%
1M Prestazione:
+12.37%
6M Prestazione:
+52.98%
1 anno Prestazione:
+77.37%
Intervallo 1D:
$26.49
$27.63
Intervallo di 1 settimana:
$24.36
$27.63
Portata 52W:
$13.36
$29.25
Immunovant Inc Stock (IMVT) Company Profile
Nome
Immunovant Inc
Settore
Industria
Telefono
917-410-3120
Indirizzo
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
27.43 | 5.40B | 0 | -464.20M | -423.09M | -2.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-20 | Iniziato | Bernstein | Mkt Perform |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | Iniziato | Truist | Hold |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-03-03 | Iniziato | Jefferies | Hold |
| 2025-01-03 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-09 | Reiterato | Oppenheimer | Outperform |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2024-03-13 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | JP Morgan | Overweight |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-13 | Aggiornamento | UBS | Neutral → Buy |
| 2023-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Iniziato | BofA Securities | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-31 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2023-02-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Downgrade | UBS | Buy → Neutral |
| 2021-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2021-08-03 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-01 | Downgrade | Stifel | Buy → Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-12 | Iniziato | Guggenheim | Buy |
| 2020-10-08 | Iniziato | Stifel | Buy |
| 2020-10-02 | Iniziato | Credit Suisse | Outperform |
| 2020-08-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Immunovant Inc Borsa (IMVT) Ultime notizie
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight - GlobeNewswire Inc.
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up - TipRanks
Immunovant (IMVT) CTO stout sells $251k in shares By Investing.com - Investing.com Canada
Van Tuyl, Immunovant’s chief legal officer, sells $128k in IMVT stock - Investing.com
Immunovant (IMVT) CTO stout sells $251k in shares - Investing.com
Immunovant (IMVT) CLO sells 5,165 shares to cover RSU tax bill - Stock Titan
[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan
Immunovant (NASDAQ: IMVT) CTO sells 10,132 shares for RSU tax obligations - Stock Titan
(IMVT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Immunovant (IMVT) grants director Frank Torti RSUs and stock options - Stock Titan
Immunovant (IMVT) director receives RSU and stock option grants - Stock Titan
Immunovant (IMVT) grants director Douglas J. Hughes RSUs and stock options - Stock Titan
Immunovant (IMVT) director granted options and RSUs in new equity awards - Stock Titan
Immunovant (IMVT) awards RSUs and stock options to director Jake Bauer - Stock Titan
Immunovant (IMVT) director receives 13,880 RSUs and 7,061 options - Stock Titan
Immunovant (IMVT) COO receives new stock options and RSU grants - Stock Titan
Immunovant (IMVT) CTO granted 96,851 options and 66,937 RSUs - Stock Titan
Immunovant (IMVT) CLO receives 59,820 options and 41,343 RSUs - Stock Titan
Immunovant (IMVT) CEO awarded new stock options and RSUs in equity grant - Stock Titan
Immunovant (IMVT) CFO awarded RSUs and 94,002 options under 2019 plan - Stock Titan
Immunovant falls on late-stage trial setback for TED therapy - MSN
Wolfe Research Maintains Immunovant(IMVT.US) With Buy Rating, Announces Target Price $47 - Moomoo
IMVT Shares Drop 2.4% After Batoclimab Fails to Meet Key Goals in Final-Stage Trial - Bitget
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - Yahoo Finance
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Cuts Target Price to $42 - Moomoo
Immunovant Inc stock: Why biotech investors are watching this closely now - AD HOC NEWS
Aberdeen Group plc Increases Stake in Immunovant, Inc. $IMVT - MarketBeat
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Immunovant (NASDAQ:IMVT) CEO Sells $342,918.90 in Stock - MarketBeat
Immunovant (IMVT) CEO Venker sells $342,854 in shares By Investing.com - Investing.com India
Immunovant (IMVT) CEO Venker sells $342,854 in shares - Investing.com
Immunovant (IMVT) CEO settles CVARs into 368,750 shares, disposes stock - Stock Titan
Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Truist reiterates Hold on Immunovant stock after trial failure By Investing.com - Investing.com India
Immunovant's treatment for eye disease fails in late-stage trials - Reuters
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data UpdateSlideshow - Seeking Alpha
IMVT: Brepocitinib advances into pivotal LPP trials as batoclimab's TED study informs Graves' strategy - TradingView
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP - Yahoo Finance
Leerink cuts Immunovant stock price target on failed TED trial By Investing.com - Investing.com Australia
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM - BioPharma Dive
Leerink cuts Immunovant stock price target on failed TED trial - Investing.com
Oppenheimer maintains Immunovant stock rating on next-gen drug focus By Investing.com - Investing.com India
Oppenheimer maintains Immunovant stock rating on next-gen drug focus - Investing.com UK
IMVT: Batoclimab missed its Phase 3 endpoint in thyroid eye disease; focus shifts to IMVT-1402 - TradingView
Immunovant Inc Azioni (IMVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):